NYSE
18.28USD
+0.59 (+3.34%)
We have scored 21 news catalysts on Arcus Biosciences, Inc. (RCUS) over the past 12 months. The biggest single-day move next to one of them came Dec 12, 2025, when RCUS closed −14.4%: “Arcus Provides Update on Phase 3 STAR-221 Study and Concentrates Its R&D Investment on Casdatifan and Emerging Inflammation and Immunology Portfolio”. Coverage across the window leans negative (average ticker sentiment −0.10). Most of the impact sits in price momentum and sector healthcare.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
2.6B
P/E
—
EPS
—
Beta
0.81
52W range
17.43-31.74
Day range
17.77–18.50
Open
17.95
Prev close
17.69
Volume
1.1M
Avg volume
1.6M
Dividend
0.00
IPO
2018-03-14
Analysts publish price targets on RCUS, and they disagree. Where the share price actually sits among them shows which of their arguments the market is buying — and which it is ignoring.
5 analyst price targets from $23 to $45
as of 2026-09-24
The market is 40% below the median target — more cautious than the analysts.
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Arcus Biosciences, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for RCUS: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company’s development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.
The reconstruction
At $18.28, the market sits 40% below the median analyst target of $42 and at the 20th percentile of published models, rejecting the bullish casdatifan story that four sell-side banks have adopted.
What the disagreement turns on
Whether casdatifan's clinical data will support a multi-billion-dollar competitive therapy in kidney cancer, and the wired data cannot settle this — consumer attention and past unit volumes cannot measure Phase III oncology outcomes.
The price pays for
It declines to pay for
Written by a language model from the published models, the reported segments and a reverse-DCF — not a recommendation, and not a house view.
Claim by claim
Computed at $25.06 on 2026-09-24 — the quote has since moved -27%, so read this as a record of what was priced in then, not now.
